KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$5.79 USD
-0.01 (-0.17%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $5.84 +0.05 (0.86%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum D VGM
Balance Sheet
Fiscal Year End for KALA BIO, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 51 | 71 | 94 | 154 | 85 |
Receivables | 0 | 0 | 15 | 10 | 12 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 9 | 5 | 5 |
Other Current Assets | 2 | 15 | 6 | 3 | 4 |
Total Current Assets | 53 | 86 | 124 | 171 | 105 |
Net Property & Equipment | 1 | 0 | 3 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 11 | 19 | 16 |
Total Assets | 56 | 87 | 139 | 222 | 154 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 3 | 5 | 2 | 3 |
Current Portion Long-Term Debt | 0 | 10 | 11 | 2 | 1 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 9 | 21 | 19 | 21 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 4 | 0 | 0 | 0 |
Total Current Liabilities | 8 | 26 | 37 | 22 | 25 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 38 | 42 | 85 | 72 | 71 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 48 | 68 | 123 | 122 | 125 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 637 | 606 | 559 | 500 | 325 |
Retained Earnings | -629 | -587 | -542 | -400 | -295 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 8 | 19 | 17 | 100 | 30 |
Total Liabilities & Shareholder's Equity | 56 | 87 | 139 | 222 | 154 |
Total Common Equity | 8 | 19 | 17 | 100 | 30 |
Shares Outstanding | 2.60 | 1.70 | 1.30 | 1.10 | 0.60 |
Book Value Per Share | 2.88 | 11.16 | 12.92 | 90.91 | 49.48 |
Fiscal Year End for KALA BIO, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 54 | 48 | 51 | 56 | 59 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 2 | 2 | 2 | 6 |
Total Current Assets | 59 | 50 | 53 | 58 | 66 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 62 | 53 | 56 | 61 | 67 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 12 | 6 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 5 | 6 | 6 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 0 | 1 | 3 | 4 |
Total Current Liabilities | 19 | 12 | 8 | 10 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 27 | 33 | 38 | 38 | 39 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 48 | 46 | 48 | 50 | 49 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 665 | 648 | 637 | 632 | 630 |
Retained Earnings | -651 | -641 | -629 | -621 | -612 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 14 | 7 | 8 | 11 | 17 |
Total Liabilities & Shareholder's Equity | 62 | 53 | 56 | 61 | 67 |
Total Common Equity | 14 | 7 | 8 | 11 | 17 |
Shares Outstanding | 4.60 | 2.80 | 2.60 | 2.50 | 2.30 |
Book Value Per Share | 2.98 | 2.38 | 2.88 | 4.49 | 7.60 |